Nabriva Therapeutics plc
NBRV
Clasificación en acciones
#39899
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Precio por acción
$0.63
Última sincronización: 2023-08-29
Capitalización bursátil
$284.20K
Cambio (1 día)
-21.25%
Cambio (1 año)
629,900.02%
País
IE
Comercio Nabriva Therapeutics plc (NBRV)
Categoría
Healthcare
Capitalización de mercado de Nabriva Therapeutics plc(NBRV)
Capitalización bursátil: $284.20K
A fecha de October 2026, Nabriva Therapeutics plc tiene una capitalización de mercado de $284.20K. Esto convierte a Nabriva Therapeutics plc en la 39899th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Nabriva Therapeutics plc desde 2023 hasta 2026
NBRV en comparación con los más populares 5 títulos stocks
| Precio por NBRV | Activo B | Capital del mercado en B | Resultados | |
|---|---|---|---|---|
$1,599,703
$323.00
|
$5.167T | +1,599,702,786,277.71% | ||
|
$1,552,563
$323.00
|
$5.015T | +1,552,563,207,547.06% | ||
|
$1,271,951
$323.00
|
$4.108T | +1,271,951,153,813.31% | ||
|
$1,208,020
$323.00
|
$3.902T | +1,208,019,739,373.68% | ||
|
$832,649
$323.00
|
$2.689T | +832,648,929,311.77% |
